Immunoglobulin G

DRUG6 trials

Conditions

Autoimmune EncephalitisDystrophic Epidermolysis BullosaEpidermolysis BullosaEpidermolysis Bullosa AcquisitaHealthy ParticipantsKawasaki DiseaseRecessive Dystrophic Epidermolysis BullosaSeptic Shock

Phase 1

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

RecruitingNCT06834035

M. Peter MarinkovichDystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita +1

Start: 2025-08-04End: 2027-03-01Target: 8Updated: 2026-05-05

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

CompletedNCT07025577

Genentech, Inc.Healthy Participants

Start: 2025-06-02End: 2025-09-03Updated: 2025-09-10

Phase 2

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

CompletedNCT04175522

Green Cross CorporationAutoimmune Encephalitis

Start: 2019-11-20End: 2020-06-11Updated: 2020-06-30

Phase 3

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

TerminatedNCT01315496

Green Cross CorporationSeptic Shock, Severe Sepsis

Start: 2009-10-31End: 2013-12-31Target: 214Updated: 2013-04-30

Phase 4

Study of Combined Therapy of Aspirin and IVIG-SN in Kawasaki Disease

CompletedNCT01524939

Green Cross CorporationKawasaki Disease

Start: 2012-01-31End: 2012-09-30Updated: 2012-09-20

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

CompletedNCT04003844

Green Cross CorporationKawasaki Disease

Start: 2019-02-01End: 2019-11-22Updated: 2020-05-21

Related Papers

Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.

2020-07-0836 citations